News

ALIPANC Online Seminar – April 13th, 14:00h CET

Speaker: Prof. Andreas Trumpp Affiliation: German Cancer Research Center (DKFZ) & HI-STEM Title: "Profiling and targeting of innervating peripheral neurons in pancreatic cancer" (Profiling and targeting of peripheral neurons innervating pancreatic cancer)  ...

Folate- and aCD47-functionalized lipid nanoparticles efficiently deliver mRNA and remodel pancreatic tumor microenvironment.

ALIPANC researchers demonstrate that functionalization of lipid nanoparticles with "don't eat me signal" blocking antibodies, such as the CD47/SIRP axis α, result in a further increase of macrophage phagocytic activity on tumor cells. In addition, enrichment of...

3rd ALIPANC Scientific Meeting on Pancreatic Cancer

The 3rd Scientific Meeting of ALIPANC brings together more than 80 experts to promote translational research in pancreatic cancer. On March 13, the 3rd scientific meeting of ALIPANC took place at the HM Sanchinarro University Hospital in Madrid, with the attendance of...

Annual Scientific Meeting 2026

March 13, 2026 Hospital Universitario HM Sanchinarro (Madrid). On-site event Scientific Coordination: Jorge Adeva Alfonso, Rafael Alvarez, Justo P. Castaño, Florian Castet, Elisa Espinet, Cristina Fillat, Carmen Guerra, Ismael Macías, Andres Muñoz, Francisco X. Real,...

CNIO Seminar: Dr. Florencia McAllister – “Cancer as an ecosystem: how microbes shape tumors”.

We are pleased to announce an upcoming seminar of special interest to the pancreatic cancer research community. On Friday, January 23, at 12:00 noon (CET), Dr. Florencia McAllister, M.D., Associate Professor of Clinical Cancer Prevention and Gastrointestinal Medical...

ALIPANC researchers conducted a study that links venous thromboembolic disease (VTE) with poorer survival in pancreatic cancer patients

The group led by Andrés Muñoz (Gregorio Marañón Hospital, Madrid) has published a subanalysis of the ONCOTHROMB12-01 study, which examines the impact of a diagnosis of venous thromboembolic disease (VTE) on the overall survival of cancer patients. A diagnosis of VTE...

Pancreatic Cancer Conference, London 2026 – Cancer Research UK

Registration is now open for the Pancreatic Cancer Conference organised by Cancer Research UK. The event will take place in London from 7–9 July....

ALPANC researchers publish study protocol comparing 3D modeling versus conventional CT

3D-PANC study protocol: Is three-dimensional imaging technology superior to computed tomography for assessing the response to neoadjuvant treatment in patients with borderline or locally advanced pancreatic adenocarcinoma? This study focuses on improving the...

New potential therapeutic target for pancreatic cancer identified by ALIPANC researchers

The study by Parejo-Alonso et al. identifies PPAR-δ as a critical transcription factor mediating pancreatic cancer cell adaptation to microenvironmental stress. Normally involved in lipid metabolism, PPAR-δ is overexpressed in pancreatic tumors and, under metabolic...

ALIPANC researchers develop a new therapeutic combination in preclinical models of pancreatic cancer.

This study conducted by researchers from Vigo presents an innovative sequential therapeutic strategy against pancreatic ductal adenocarcinoma, one of the most lethal cancers due to its stromal barrier that prevents drug penetration. The novelty lies in the biphasic...